Education
About Us
Working with TipRanks
Follow Us
Laura Clague Insider Profile
4 Followers
Laura Clague, CFO at Travere Therapeutics, holds 104.79K shares in Standard BioTools (Ticker: LAB), holds 35.66K shares in Travere Therapeutics (Ticker: TVTX), holds 286.31K shares in Genasys (Ticker: GNSS).
Laura Clague has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Laura Clague holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Laura Clague
Laura Clague's Trading History
Travere Therapeutics
May 12, 2022
CFO
Uninformative Sell
47.32K
$645.00K
Standard BioTools
Jun 16, 2023
Director
Uninformative Buy
―
$121.56K
Genasys
Apr 27, 2022
Director
Uninformative Buy
66.50K
$690.01K
Turtle Beach
―
Director
―
$0.00
List of latest transactions for each holding click on a transaction to see Laura Clague's performance on stock
You May Also Like
Laura Clague insider profile FAQ
What is the percentage of profitable transactions made by Laura Clague?
The percentage of profitable transactions made by Laura Clague is ―.
What is the average return per transaction made by Laura Clague?
The average return per transaction made by Laura Clague is ―.
What stocks does Laura Clague hold?
Laura Clague holds: TVTX, LAB, GNSS, TBCH stocks.
What was Laura Clague’s latest transaction?
Laura Clague latest transaction was an Uninformative Buy of ―.
What was Laura Clague's most profitable transaction?
Laura Clague’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Laura Clague's role in Travere Therapeutics?
Laura Clague's role in Travere Therapeutics is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.